Skip to main content

Table 2 Patient characteristics

From: Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review

Reference % female Mean age in years (SD) [range] Cancer site (%) Common chemotherapeutic agents* (%)
Hesketh [18] 71 Median 54 (NR) [25–81] Breast (55), other (45) Doxorubicin (15), cyclophosphamide (26), 5-FU (43), vincristine (23), methotrexate (14)
Gralla [19] 72 55 (11) [18-NR] Breast (57), lung (80 < bladder (5), colon (4), rectal (3), small-cell lung (3), gastric (3) Cyclophosphamide (63), doxorubicin (48), cisplatin (18), methotrexate (16), carboplatin (12)
Kim [20] 37 55.6 (11) [18-NR] Lung (26), gastric (11), other (29) 5-FU plus cisplatin (27), cisplatin plus the following: taxol, docetaxel, etoposide and ifosfomide, etoposide, gemcitabine, docetaxel plus 5-FU (73)
  1. NR: not reported; SD: standard deviation. *received by >10% of patients.